Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor : Final appraisal determination committee papers
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.